Detalles de la búsqueda
1.
mTOR inhibitors a potential predisposing factor for chronic hepatitis E: Results from the prospective collaborative CHES study (Chronic Hepatitis EScreening in patients with immune impairment and increased transaminases levels).
Gastroenterol Hepatol
; 46(10): 764-773, 2023 Dec.
Artículo
en Inglés, Español
| MEDLINE | ID: mdl-36731726
2.
Etiologies and Features of Acute Viral Hepatitis in Spain.
Clin Gastroenterol Hepatol
; 19(5): 1030-1037, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32663522
3.
Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules.
J Hepatol
; 70(5): 874-884, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30684506
4.
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
J Hepatol
; 71(4): 666-672, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31203153
5.
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
J Hepatol
; 66(6): 1138-1148, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28189751
6.
Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease.
Am J Gastroenterol
; 112(9): 1400-1409, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28585554
7.
Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study.
Transpl Int
; 30(10): 1041-1050, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28608619
8.
Sofosbuvir and daclatasvir in mono- and HIV-coinfected patients with recurrent hepatitis C after liver transplant.
Ann Hepatol
; 16(1): 86-93, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28051797
9.
Corrigendum to "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules" [J Hepatol (2019) 874-884].
J Hepatol
; 74(2): 491, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33317846
10.
Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure.
JHEP Rep
; 6(3): 100994, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38357421
11.
Emergency department contribution to HCV elimination in the Iberian Peninsula.
Int J Emerg Med
; 17(1): 5, 2024 Jan 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38178000
12.
Integrating viral hepatitis management into the emergency department: A further step towards viral hepatitis elimination.
JHEP Rep
; 6(1): 100932, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38074506
13.
Analysis of the reasons for requesting HIV serology in the emergency department other than those defined in the targeted screening strategy of the "Urgències VIHgila" program and its potential inclusion in a future consensus document.
Enferm Infecc Microbiol Clin (Engl Ed)
; 2024 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38519281
14.
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.
Aliment Pharmacol Ther
; 2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38695095
15.
Barriers to linkage to care in hepatitis C patients with substance use disorders and dual diagnoses, despite centralized management.
Therap Adv Gastroenterol
; 14: 17562848211016563, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34471422
16.
Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure.
Antiviral Res
; 174: 104694, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31857134
17.
Sofosbuvir and Daclatasvir in Mono-and HIV-coinfected Patients with Recurrent Hepatitis C After Liver Transplant
Ann. hepatol
; 16(1): 86-93, Jan.-Feb. 2017. graf
Artículo
en Inglés
| LILACS | ID: biblio-838090
Resultados
1 -
17
de 17
1
Próxima >
>>